Clinical Trial Update: A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO) [NA]

View source ↗

Summary

A first-in-human clinical trial to evaluate a novel CRISPR RNA-editing therapy for MeCP2 duplication syndrome has begun, with HuidaGene Therapeutics sponsoring …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mecp2 Duplication Syndrome

Drugs mentioned

• CRISPR RNA-editing therapy

Snippet

Sponsor: HuidaGene Therapeutics Co., Ltd. | Conditions: MECP2 Duplication Syndrome | NA | Status: RECRUITING